{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:09:22Z","timestamp":1791119362263,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korean Government","award":["NRF-2012-R1A1B3004095"],"award-info":[{"award-number":["NRF-2012-R1A1B3004095"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.canlet.2014.11.011","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T16:34:54Z","timestamp":1415637294000},"page":"937-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"PB","title":["miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma"],"prefix":"10.1016","volume":"356","author":[{"given":"Tae Hoen","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-ye","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-yeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeyoun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwangil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jung","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.11.011_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","article-title":"microRNAs as oncogenes and tumor suppressors","volume":"302","author":"Zhang","year":"2007","journal-title":"Dev. Biol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.11.011_bib0020","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-07-1731","article-title":"MicroRNA expression profiles in serous ovarian carcinoma","volume":"14","author":"Nam","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0025","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","article-title":"MicroRNA signatures in human ovarian cancer","volume":"67","author":"Iorio","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0030","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1056\/NEJMoa0803785","article-title":"Dicer, Drosha, and outcomes in patients with ovarian cancer","volume":"359","author":"Merritt","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.11.011_bib0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1208\/s12248-009-9145-9","article-title":"Therapeutic microRNA strategies in human cancer","volume":"11","author":"Li","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.canlet.2014.11.011_bib0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"c-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"O'Donnell","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2014.11.011_bib0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/cgt.2008.8","article-title":"Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?","volume":"15","author":"Tong","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.canlet.2014.11.011_bib0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs \u2013 microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.11.011_bib0055","first-page":"882","article-title":"Reduced accumulation of specific microRNAs in colorectal neoplasia","volume":"1","author":"Michael","year":"2003","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0060","first-page":"170","article-title":"miR-145-mediated suppression of cell growth, invasion and metastasis","volume":"2","author":"Sachdeva","year":"2010","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0065","doi-asserted-by":"crossref","first-page":"32582","DOI":"10.1074\/jbc.M702806200","article-title":"Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells","volume":"282","author":"Shi","year":"2007","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2014.11.011_bib0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/mc.20235","article-title":"HMGA2 overexpression in non-small cell lung cancer","volume":"46","author":"Meyer","year":"2007","journal-title":"Mol. Carcinog"},{"key":"10.1016\/j.canlet.2014.11.011_bib0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1098-2744(199707)19:3<153::AID-MC2>3.0.CO;2-F","article-title":"Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade","volume":"19","author":"Rogalla","year":"1997","journal-title":"Mol. Carcinog"},{"key":"10.1016\/j.canlet.2014.11.011_bib0080","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00535-003-1221-9","article-title":"High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms","volume":"38","author":"Abe","year":"2003","journal-title":"J. Gastroenterol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-1119(01)00689-8","article-title":"Molecular biology of HMGA proteins: hubs of nuclear function","volume":"277","author":"Reeves","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2014.11.011_bib0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cell.2006.05.052","article-title":"A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation","volume":"126","author":"Narita","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.11.011_bib0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/modpathol.2010.49","article-title":"HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma","volume":"23","author":"Mahajan","year":"2010","journal-title":"Mod. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAS.0b013e3181be5d72","article-title":"HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes","volume":"34","author":"Wei","year":"2010","journal-title":"Am. J. Surg. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0105","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.1137999","article-title":"Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation","volume":"315","author":"Mayr","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.11.011_bib0110","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1677\/ERC-09-0184","article-title":"The role of let-7 in cell differentiation and cancer","volume":"17","author":"Boyerinas","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2014.11.011_bib0115","doi-asserted-by":"crossref","first-page":"11400","DOI":"10.1073\/pnas.0704372104","article-title":"Let-7 expression defines two differentiation stages of cancer","volume":"104","author":"Shell","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.11.011_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int. J. Gynecol. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0130","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.11.011_bib0135","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1078-0432.CCR-09-2166","article-title":"Comprehensive microRNA profiling for head and neck squamous cell carcinomas","volume":"16","author":"Hui","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0140","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bjc.2012.294","article-title":"Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation","volume":"107","author":"Hall","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.11.011_bib0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2559.2010.03686.x","article-title":"Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours","volume":"57","author":"Kim","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2014.11.011_bib0150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-09-2021","article-title":"MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1","volume":"70","author":"Sachdeva","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.11.011_bib0155","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1582-4934.2010.01148.x","article-title":"miRNA profiling along tumour progression in ovarian carcinoma","volume":"15","author":"Vaksman","year":"2011","journal-title":"J. Cell. Mol. Med"},{"key":"10.1016\/j.canlet.2014.11.011_bib0160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbrc.2013.10.053","article-title":"MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1","volume":"441","author":"Wu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.canlet.2014.11.011_bib0165","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih Ie","year":"2004","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0170","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/path.1563","article-title":"A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes","volume":"203","author":"Russell","year":"2004","journal-title":"J. Pathol"},{"key":"10.1016\/j.canlet.2014.11.011_bib0175","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1349-7006.2007.00618.x","article-title":"Downregulation of microRNAs-143 and -145 in B-cell malignancies","volume":"98","author":"Akao","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2014.11.011_bib0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/cdd.2009.117","article-title":"miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells","volume":"17","author":"Spizzo","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.canlet.2014.11.011_bib0185","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1073\/pnas.0808042106","article-title":"p53 represses c-Myc through induction of the tumor suppressor miR-145","volume":"106","author":"Sachdeva","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.11.011_bib0190","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ijc.23491","article-title":"HMGA2 gene is a promising target for ovarian cancer silencing therapy","volume":"123","author":"Malek","year":"2008","journal-title":"Int. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514006673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514006673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T17:53:38Z","timestamp":1538070818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514006673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0304383514006673"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.11.011","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}